OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On August 20, 2020, OpGen, Inc. updated its corporate presentation, which it made available on its website. A copy of the presentation is furnished as Exhibit 99.1 to this report.
Item 8.01 Other Events.
On August 20, 2020, OpGen, Inc. issued a press release announcing its subsidiary, Curetis GmbH, has obtained the CE mark certification in the European Union for its SARS-CoV-2 test kit that tests for the detection of SARS-CoV-2, the virus that causes COVID-19. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Document | ||
| 99.1 | Corporate Presentation dated August 2020 | ||
| 99.2 | Press Release issued by OpGen, Inc. dated August 20, 2020 | ||
The information included in Item 7.01 of this report and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
OPGEN INC Exhibit
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 August 2020 OpGen Corporate Overview Forward looking statements disclaimer ©2020 OpGen ,…
To view the full exhibit click here
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
